Harrow Inc (HROW)

$39.52 +0.05 (0.11%)
Market Cap 1.48B
Revenue (ttm) 272.30M
Net Income (ttm) -5.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 370.65
Profit Margin -1.89%
Debt to Equity Ratio 19.69
Volume 920,400
Avg Vol 689,758
Day's Range N/A - N/A
Shares Out 37.49M
Stochastic %K 34%
Beta 0.28
Analysts Strong Sell
Price Target $65.57

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy Aug. 19 at 11:14 AM
$HROW $ETON is very well managed company but not undervalued anymore. Time to lock 1,400% profits. Nailed it. HROW will outperfrom ETON very heavily for the next 1-2 years.
0 · Reply
flash9875
flash9875 Aug. 18 at 11:29 PM
$HROW its all self evident...
0 · Reply
Finnish_boy
Finnish_boy Aug. 18 at 8:07 AM
$HROW Stock higher before Q3 earnings than now. Stock$100 next year. And $175-200 by 2030. I think S&P500 makes some correction or being flat before mid-terms but NVIDIA earnings report positive catalyst. S&P500 heading well over 8,000 late this year or early next year. Yields sre very high but AI boom massive. Cant avoid that.
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 18 at 1:35 AM
$HROW I will take $88 in a year .. will keep DCA ing when and where I can
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 11:12 PM
$HROW
2 · Reply
Tennis_4567
Tennis_4567 Aug. 17 at 8:02 PM
$HROW wonder when we’ll finally set $40 as a low point never to be seen again.
2 · Reply
Finnish_boy
Finnish_boy Aug. 17 at 11:50 AM
$HROW https://investors.eyepoint.bio/news-releases/news-release-details/eyepoint-announces-topline-data-lugano-first-two-pivotal-phase-3 👍
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:26 AM
$HROW https://x.com/Bullstkpicks/status/2087297752049012924
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:26 AM
$HROW .
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:25 AM
$HROW
0 · Reply
Latest News on HROW
Harrow Earnings Call Transcript: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Harrow Earnings Call Transcript: Q2 2026

Harrow Earnings release: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Harrow Earnings release: Q2 2026

Harrow Quarterly report: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Harrow Quarterly report: Q2 2026

Harrow Slides: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Harrow Slides: Q2 2026

Harrow reports Q2 EPS (46c), consensus (24c)

2026-08-10T21:10:13.000Z - 8 days ago

Harrow reports Q2 EPS (46c), consensus (24c)

Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M

2026-08-06T13:06:39.000Z - 12 days ago

Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M

VTRS

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Jul 27, 2026, 7:00 AM EDT - 23 days ago

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data

2026-07-20T13:25:22.000Z - 4 weeks ago

Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Jul 20, 2026, 7:00 AM EDT - 4 weeks ago

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow announces commercial launch of Byooviz in the U.S.

2026-07-01T11:20:11.000Z - 7 weeks ago

Harrow announces commercial launch of Byooviz in the U.S.

Harrow announces commercial launch of BYOOVIZ in U.S.

2026-07-01T11:11:21.000Z - 7 weeks ago

Harrow announces commercial launch of BYOOVIZ in U.S.

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 9:40 AM EDT - 2 months ago

Harrow Transcript: 46th Annual William Blair Growth Stock Conference

Harrow Slides: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 9:40 AM EDT - 2 months ago

Harrow Slides: 46th Annual William Blair Growth Stock Conference

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

May 27, 2026, 7:00 AM EDT - 3 months ago

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

Harrow CEO buys $302K, CFO buys $104.7K in common stock

2026-05-15T14:31:15.000Z - 3 months ago

Harrow CEO buys $302K, CFO buys $104.7K in common stock

Harrow price target lowered to $60 from $65 at B. Riley

2026-05-14T13:54:22.000Z - 3 months ago

Harrow price target lowered to $60 from $65 at B. Riley

Harrow price target lowered to $88 from $91 at Cantor Fitzgerald

2026-05-13T15:22:03.000Z - 3 months ago

Harrow price target lowered to $88 from $91 at Cantor Fitzgerald

Harrow Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Harrow Earnings Call Transcript: Q1 2026

Harrow Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Harrow Earnings release: Q1 2026

Harrow Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Harrow Quarterly report: Q1 2026

Harrow Shareholder letter: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Harrow Shareholder letter: Q1 2026

Harrow Slides: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Harrow Slides: Q1 2026

Harrow reports Q1 EPS (74c) vs. (50c) last year

2026-05-11T20:41:15.000Z - 3 months ago

Harrow reports Q1 EPS (74c) vs. (50c) last year

Harrow Announces First Quarter 2026 Financial Results

May 11, 2026, 4:05 PM EDT - 3 months ago

Harrow Announces First Quarter 2026 Financial Results

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Harrow Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Harrow Proxy statement: Proxy filing

Harrow Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Harrow Proxy statement: Proxy filing

Harrow announces issuance of J-Code for Iopidine 1%

2026-04-16T11:57:26.000Z - 4 months ago

Harrow announces issuance of J-Code for Iopidine 1%

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Harrow selects LogiCare3PL as distribution partner

2026-04-14T14:35:13.000Z - 4 months ago

Harrow selects LogiCare3PL as distribution partner

LogiCare3PL Selected as Distribution Partner by Harrow

Apr 14, 2026, 10:30 AM EDT - 4 months ago

LogiCare3PL Selected as Distribution Partner by Harrow

Harrow management to meet virtually with BTIG

2026-04-09T20:33:07.000Z - 4 months ago

Harrow management to meet virtually with BTIG

Harrow management to meet virtually with BTIG

2026-04-09T20:25:15.000Z - 4 months ago

Harrow management to meet virtually with BTIG

Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T13:01:36.000Z - 4 months ago

Harrow price target lowered to $65 from $74 at B. Riley

Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T12:28:56.000Z - 4 months ago

Harrow price target lowered to $65 from $74 at B. Riley

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

Mar 24, 2026, 4:57 PM EDT - 5 months ago

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Mar 24, 2026, 8:15 AM EDT - 5 months ago

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Harrow Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:40 AM EDT - 5 months ago

Harrow Transcript: Leerink Global Healthcare Conference 2026

Harrow Slides: FY 2026

Mar 10, 2026, 8:40 AM EDT - 5 months ago

Harrow Slides: FY 2026

Harrow price target lowered to $60 from $70 at Lake Street

2026-03-04T13:45:34.000Z - 5 months ago

Harrow price target lowered to $60 from $70 at Lake Street

Harrow price target lowered to $91 from $94 at Cantor Fitzgerald

2026-03-04T13:35:02.000Z - 5 months ago

Harrow price target lowered to $91 from $94 at Cantor Fitzgerald

Harrow price target lowered to $62 from $66 at Ladenburg

2026-03-04T12:41:07.000Z - 5 months ago

Harrow price target lowered to $62 from $66 at Ladenburg

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 6 months ago

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Harrow Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Harrow Earnings Call Transcript: Q4 2025

Harrow Shareholder letter: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Harrow Shareholder letter: Q4 2025

Harrow Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Harrow Annual report: Q4 2025

Harrow Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Harrow Earnings release: Q4 2025

Harrow Slides: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Harrow Slides: Q4 2025

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Mar 3, 2026, 7:00 AM EST - 6 months ago

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Mar 2, 2026, 4:05 PM EST - 6 months ago

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Feb 18, 2026, 7:00 AM EST - 6 months ago

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Feb 17, 2026, 7:00 AM EST - 6 months ago

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Feb 2, 2026, 7:00 AM EST - 7 months ago

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 3:00 PM EST - 9 months ago

Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference

Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 9 months ago

Harrow to Present at Two Investor Conferences in December

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 9 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow Earnings Call Transcript: Q3 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Harrow Earnings Call Transcript: Q3 2025

Harrow Quarterly report: Q3 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Harrow Quarterly report: Q3 2025

Harrow Earnings release: Q3 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Harrow Earnings release: Q3 2025

Harrow Slides: Q3 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Harrow Slides: Q3 2025

Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 10 months ago

Harrow Announces Third Quarter 2025 Financial Results

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 11 months ago

ImprimisRx Announces Leadership Changes

Harrow Transcript: Investor Day 2025

Sep 26, 2025, 11:30 AM EDT - 11 months ago

Harrow Transcript: Investor Day 2025

Harrow Slides: FY 2025

Sep 26, 2025, 11:30 AM EDT - 11 months ago

Harrow Slides: FY 2025

Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 11 months ago

Harrow to Acquire Melt Pharmaceuticals

Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 11 months ago

Harrow Launches Harrow Access for All (HAFA)

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 1 year ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 1 year ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 8:30 AM EDT - 1 year ago

Harrow Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Harrow Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q2 2025

Harrow Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Harrow Quarterly report: Q2 2025

Harrow Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings release: Q2 2025

Harrow Slides: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Harrow Slides: Q2 2025

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow Slides: Corporate Presentation

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Harrow Slides: Corporate Presentation

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 1 year ago

Harrow to Present at Two Investor Conferences in May

Harrow Earnings Call Transcript: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q1 2025

Harrow Quarterly report: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Quarterly report: Q1 2025

Harrow Earnings release: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings release: Q1 2025

Harrow Slides: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Slides: Q1 2025

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Harrow Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Harrow Proxy statement: Proxy Filing

Harrow Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Harrow Proxy statement: Proxy Filing

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 1 year ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q4 2024

Harrow Earnings release: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings release: Q4 2024

Harrow Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Annual report: Q4 2024

Harrow Slides: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Slides: Q4 2024

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 1 year ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Finnish_boy
Finnish_boy Aug. 19 at 11:14 AM
$HROW $ETON is very well managed company but not undervalued anymore. Time to lock 1,400% profits. Nailed it. HROW will outperfrom ETON very heavily for the next 1-2 years.
0 · Reply
flash9875
flash9875 Aug. 18 at 11:29 PM
$HROW its all self evident...
0 · Reply
Finnish_boy
Finnish_boy Aug. 18 at 8:07 AM
$HROW Stock higher before Q3 earnings than now. Stock$100 next year. And $175-200 by 2030. I think S&P500 makes some correction or being flat before mid-terms but NVIDIA earnings report positive catalyst. S&P500 heading well over 8,000 late this year or early next year. Yields sre very high but AI boom massive. Cant avoid that.
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 18 at 1:35 AM
$HROW I will take $88 in a year .. will keep DCA ing when and where I can
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 11:12 PM
$HROW
2 · Reply
Tennis_4567
Tennis_4567 Aug. 17 at 8:02 PM
$HROW wonder when we’ll finally set $40 as a low point never to be seen again.
2 · Reply
Finnish_boy
Finnish_boy Aug. 17 at 11:50 AM
$HROW https://investors.eyepoint.bio/news-releases/news-release-details/eyepoint-announces-topline-data-lugano-first-two-pivotal-phase-3 👍
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:26 AM
$HROW https://x.com/Bullstkpicks/status/2087297752049012924
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:26 AM
$HROW .
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 17 at 3:25 AM
$HROW
0 · Reply
Finnish_boy
Finnish_boy Aug. 16 at 6:42 PM
$HROW Less than a year post-launch, TRYPTYR has already captured approximately 5% market share
1 · Reply
Fullback
Fullback Aug. 16 at 12:10 PM
$HROW Investors need to read this thread. Its a great discussion and represents exactly what the market is debating right now concerning price discovery.
0 · Reply
Finnish_boy
Finnish_boy Aug. 16 at 8:08 AM
$HROW Harrow 3x in 2 years. 5x potential in 4 years.
1 · Reply
Finnish_boy
Finnish_boy Aug. 15 at 9:52 PM
$HROW This guy flexing here, telling that he was right about HROW vs ETON. He was extremely lucky with that prediction, HROW should be 2x today's price. Then he flex that he bought ETON at $2 .. why sold at $5 .. stock today $58.. i am happy every dollar that people make. But not happy this kind flexing here where there are no credits to do that.
0 · Reply
alexpitti
alexpitti Aug. 15 at 4:22 PM
i don't understand $HROW yes sometimes you have companies in the dredges of clinical trials and 510k approvals, but harrow just buys drugs and commercializes. so i don't understand the losses
1 · Reply
flash9875
flash9875 Aug. 15 at 3:38 PM
$HROW It’s all about the revenue…not the charts…
0 · Reply
Tennis_4567
Tennis_4567 Aug. 15 at 10:40 AM
$HROW @Thelonius_Stonk I have a buddy who sees the HROW chart as a long term pennant pattern playing out. Thinks we’ll see it either break up or down later this year or early next. Thoughts?
1 · Reply
Finnish_boy
Finnish_boy Aug. 15 at 8:44 AM
$HROW https://mvcinvesting.substack.com/p/harrow-hrow-q2-2026-earnings-review
0 · Reply
Finnish_boy
Finnish_boy Aug. 14 at 10:13 PM
$HROW @Dbarnyard Now chill and calm down. Dont lose your eton gains right away! Wait , you didnt own a lot of ETON shares? What🤣
1 · Reply
Finnish_boy
Finnish_boy Aug. 14 at 10:08 PM
$HROW $ETON Yes you and CFONTINA were so right.. well done my American boys.. how much did you made money with this call? Let me know..Congrats again. I have called so many bets rights but nobody cares bc it's all about luck.. yes you were lucky my friends.
0 · Reply
Dbarnyard
Dbarnyard Aug. 14 at 8:24 PM
$HROW $ETON Guess it finally happened. Anyone who was laughing at me can apologize now, especially the Fin guy...
2 · Reply
Finnish_boy
Finnish_boy Aug. 14 at 9:33 AM
$HROW $100 stock next year with normal execution. $100 stock in 2028 with awful execution. You can't avoid the gains🤑
2 · Reply